102 related articles for article (PubMed ID: 12785127)
1. The need for reappraisal of type 2 diabetes mellitus management.
Wyne KL
Postgrad Med; 2003 May; Spec No():5-14. PubMed ID: 12785127
[TBL] [Abstract][Full Text] [Related]
2. Management of type 2 diabetes mellitus: is it time for a paradigm shift?
Wyne KL
Metab Syndr Relat Disord; 2004; 2(4):251-62. PubMed ID: 18370694
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance syndrome. Description, pathogenesis, and management.
Miller JL
Postgrad Med; 2003 May; Spec No():27-34. PubMed ID: 12785129
[TBL] [Abstract][Full Text] [Related]
4. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Wyne KL; Drexler AJ; Miller JL; Bell DS; Braunstein S; Nuckolls JG
Postgrad Med; 2003 May; Spec No():63-72. PubMed ID: 12785133
[TBL] [Abstract][Full Text] [Related]
5. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Kudzma DJ
Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
Bell DS
Postgrad Med; 2003 May; Spec No():35-44. PubMed ID: 12785130
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Pathak R; Afaq A; Blonde L
Am J Manag Care; 2002 Oct; 8(16 Suppl):S483-94. PubMed ID: 12408411
[TBL] [Abstract][Full Text] [Related]
8. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Weissman P
Am J Cardiol; 2002 Sep; 90(5A):42G-50G. PubMed ID: 12231078
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitizers.
Zangeneh F; Kudva YC; Basu A
Mayo Clin Proc; 2003 Apr; 78(4):471-9. PubMed ID: 12683699
[TBL] [Abstract][Full Text] [Related]
11. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
Noble J; Baerlocher MO; Silverberg J
Can Fam Physician; 2005 May; 51(5):683-7. PubMed ID: 15934272
[TBL] [Abstract][Full Text] [Related]
12. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Peters AL
Am J Manag Care; 2001 Apr; 7(3 Suppl):S87-95; quiz S96-7. PubMed ID: 11310177
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
14. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Lebovitz HE
Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
16. Durability of glycemic control: a feature of the thiazolidinediones.
Serdy S; Abrahamson MJ
Diabetes Technol Ther; 2004 Apr; 6(2):179-89. PubMed ID: 15117584
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
18. [Clinical difference between thiazolidinediones and biguanides].
Hotta N
Nihon Rinsho; 2001 Nov; 59(11):2219-27. PubMed ID: 11712411
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
20. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Brown DL; Brillon D
J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
